Proteomics as a Quality Control Tool of Pharmaceutical Probiotic Bacterial Lysate Products

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Klein, Günter ^a   Schanstra, Joost P ^b,c   Hoffmann, Janosch ^d   Mischak, Harald ^d,e   Siwy, Justyna ^d,f   Zimmermann, Kurt ^g  

^a UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

^b INSERM   (France)

^c UNIVERSITÉ PAUL SABATIER   (France)

^d Mosaiques Diagnostics   (Germany)

^e UNIVERSITY OF GLASGOW   (United Kingdom)

^f CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^g SymbioPharm GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; BACTERIUM LYSATE; CASEIN; FUNGAL PROTEIN; MICROBE ASSOCIATED MOLECULAR PATTERN; PROBIOTIC AGENT; SOYBEAN PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BACTERIAL MEMBRANE; BACTERIAL STRAIN; CAPILLARY ELECTROPHORESIS; CONTROLLED STUDY; CULTURE MEDIUM; CYTOPLASM; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; INNATE IMMUNITY; MASS SPECTROMETRY; NONHUMAN; PROTEIN CONTENT; PROTEIN DETERMINATION; PROTEIN LOCALIZATION; PROTEOMICS; QUALITY CONTROL; REPRODUCIBILITY; SEQUENCE ANALYSIS; BACTERIUM; METABOLISM;

BACTERIA (MICROORGANISMS); ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; GLYCINE MAX;

BACTERIA; ELECTROPHORESIS, CAPILLARY; MASS SPECTROMETRY; PROBIOTICS; PROTEOMICS; QUALITY CONTROL;

EID: 84879201623     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0066682     Document Type: Article

References (46)

1. Collado MC, Isolauri E, Salminen S, Sanz Y, (2009) The impact of probiotic on gut health. Curr Drug Metab 10: 68-78.
2. Gaggia F, Mattarelli P, Biavati B, (2010) Probiotics and prebiotics in animal feeding for safe food production. Int J Food Microbiol 141Suppl 1: S15-S28.
3. Santini C, Baffoni L, Gaggia F, Granata M, Gasbarri R, et al. (2010) Characterization of probiotic strains: an application as feed additives in poultry against Campylobacter jejuni. Int J Food Microbiol 141Suppl 1: S98-108.
4. Indrio F, Neu J, (2011) The intestinal microbiome of infants and the use of probiotics. Curr Opin Pediatr 23: 145-150.
5. Arbeitsgruppe BGVV, (2000) Probiotische Mikroorganismenkulturen in Lebensmitteln. Ernährungs Umschau 47: 191-195.
6. Sanders ME, (2008) Probiotics: definition, sources, selection, and uses. Clin Infect Dis 46Suppl 2: S58-S61.
7. Dehlink E, Domig KJ, Loibichler C, Kampl E, Eiwegger T, et al. (2007) Heat- and formalin-inactivated probiotic bacteria induce comparable cytokine patterns in intestinal epithelial cell-leucocyte cocultures. J Food Prot 70: 2417-2421.
8. Ohashi Y, Ushida K, (2009) Health-beneficial effects of probiotics: Its mode of action. Anim Sci J 80: 361-371.
9. Ouwehand AC, Salminen S, Isolauri E, (2002) Probiotics: an overview of beneficial effects. Antonie Van Leeuwenhoek 82: 279-289.
10. Sherman PM, Ossa JC, Johnson-Henry K, (2009) Unraveling mechanisms of action of probiotics. Nutr Clin Pract 24: 10-14.
11. Enck P, Zimmermann K, Menke G, Muller-Lissner S, Martens U, et al. (2008) A mixture of Escherichia coli (DSM 17252) and Enterococcus faecalis (DSM 16440) for treatment of the irritable bowel syndrome--a randomized controlled trial with primary care physicians. Neurogastroenterol Motil 20: 1103-1109.
12. Zhang L, Li N, Caicedo R, Neu J, (2005) Alive and dead Lactobacillus rhamnosus GG decrease tumor necrosis factor-alpha-induced interleukin-8 production in Caco-2 cells. J Nutr 135: 1752-1758.
13. Lau S, Gerhold K, Zimmermann K, Ockeloen CW, Rossberg S, et al. (2012) Oral application of bacterial lysate in infancy decreases the risk of atopic dermatitis in children with 1 atopic parent in a randomized, placebo-controlled trial. J Allergy Clin Immunol 129: 1040-1047.
14. Thomsen A, Loppnow H, (1995) Cytokine production by mononuclear cells following stimulation with a peptide-containing, endotoxin-free Escherichia coli extract. Arzneimittelforschung 45: 657-661.
15. Bioray (2013) CytoFlora™. Available: http://www.bioray.com/cytoflora/.Accessed 23 April 2013.
16. Del-Immune V ® (2013) Del-Immune V ®. Available: http://www.delimmune.com/research/.Accessed 23 April 2013.
17. Cazzola M, Capuano A, Rogliani P, Matera MG, (2012) Bacterial lysates as a potentially effective approach in preventing acute exacerbation of COPD. Curr Opin Pharmacol 12: 300-308.
18. Hamilton-Miller JM, Shah S, Winkler JT, (1999) Public health issues arising from microbiological and labelling quality of foods and supplements containing probiotic microorganisms. Public Health Nutr 2: 223-229.
19. Leuschner RGK, Robinson TP, Hugas M, Cocconcelli PS, Richard-Forget F, et al. (2010) Qualified presumption of safety (QPS): a generic risk assessment approach for biological agents notified to the European Food Safety Authority (EFSA). Trends in Food Science & Technology 21: 425-435.
20. AMG (2013) Arzneimittelgesetz in der Fassung der Bekanntmachung vom 12. Dezember 2005 (BGBl. I S. 3394), das durch Artikel 1 der Verordnung vom 25. März 2013 (BGBl. I S. 627) geändert worden ist. Available: http://www.gesetze-im-internet.de/amg_1976/. Accessed 12 April 2013.
21. Aires J, Anglade P, Baraige F, Zagorec M, Champomier-Vergès MC, et al. (2010) Proteomic comparison of the cytosolic proteins of three Bifidobacterium longum human isolates and B. longum NCC2705. BMC microbiology 10.
22. Savijoki K, Lietzén N, Kankainen M, Alatossava T, Koskenniemi K, et al. (2011) Comparative proteome cataloging of Lactobacillus rhamnosus strains GG and Lc705. Journal of Proteome Research 10: 3460-3473.
23. Mischak H, Schanstra JP, (2011) CE-MS in biomarker discovery, validation, and clinical application. Proteomics Clin Appl 5: 9-23.
24. Mischak H, Vlahou A, Ioannidis JP, (2013) Technical aspects and inter-laboratory variability in native peptide profiling: The CE-MS experience. Clin Biochem 46: 432-443.
25. Carty DM, Siwy J, Brennand JE, Zürbig P, Mullen W, et al. (2011) Urinary proteomics for prediction of preeclampsia. Hypertension 57: 561-569.
26. Good DM, Zürbig P, Argiles A, Bauer HW, Behrens G, et al. (2010) Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease. Mol Cell Proteomics 9: 2424-2437.
27. Wittke S, Fliser D, Haubitz M, Bartel S, Krebs R, et al. (2003) Determination of peptides and proteins in human urine with capillary electrophoresis-mass spectrometry, a suitable tool for the establishment of new diagnostic markers. J Chromatogr A 1013: 173-181.
28. Jantos-Siwy J, Schiffer E, Brand K, Schumann G, Rossing K, et al. (2009) Quantitative Urinary Proteome Analysis for Biomarker Evaluation in Chronic Kidney Disease. J Proteome Res 8: 268-281.
29. Siwy J, Mullen W, Golovko I, Franke J, Zürbig P, (2011) Human urinary peptide database for multiple disease biomarker discovery. Proteomics Clin Appl 5: 367-374.
30. Zürbig P, Renfrow MB, Schiffer E, Novak J, Walden M, et al. (2006) Biomarker discovery by CE-MS enables sequence analysis via MS/MS with platform-independent separation. Electrophoresis 27: 2111-2125.
31. Giese T, Zimmermann K, Meuer SC, (2003) Functional characterization of pro-biotic pharmaceuticals by quantitative analysis of gene expression. Arzneimittelforschung 53: 385-391.
32. Albalat A, Mischak H, Mullen W, (2011) Clinical application of urinary proteomics/peptidomics. Expert Rev Proteomics 8: 615-629.
33. Schiffer E, (2007) Biomarkers for prostate cancer. World J Urol 25: 557-562.
34. Zürbig P, Mischak H (2008) Biomarker discovery. In: Soloviev M, Shaw C, Andren PE, editors. Peptidomics: Methods and applications. Hoboken, New Jersey:John Wiley & Sons, Inc. pp. 319-339.
35. Zürbig P, Mischak H, (2008) Capillary electrophoresis coupled to mass spectrometry for biomarker discovery and diagnosis of kidney diseases. Contrib Nephrol 160: 107-126.
36. Theodorescu D, Fliser D, Wittke S, Mischak H, Krebs R, et al. (2005) Pilot study of capillary electrophoresis coupled to mass spectrometry as a tool to define potential prostate cancer biomarkers in urine. Electrophoresis 26: 2797-2808.
37. Neuhoff N, Kaiser T, Wittke S, Krebs R, Pitt A, et al. (2004) Mass spectrometry for the detection of differentially expressed proteins: a comparison of surface-enhanced laser desorption/ionization and capillary electrophoresis/mass spectrometry. Rapid Communications in Mass Spectrometry 18: 149-156.
38. Volz T, Nega M, Buschmann J, Kaesler S, Guenova E, et al. (2010) Natural Staphylococcus aureus-derived peptidoglycan fragments activate NOD2 and act as potent costimulators of the innate immune system exclusively in the presence of TLR signals. FASEB J 24: 4089-4102.
39. Volz T, Biedermann T, (2012) Elucidating the role of the innate immune system on atopic dermatitis- current concepts and evolving perspectives. Allegro J 21: 470-478.
40. Hoffmann J, Akira S, (2013) Innate immunity. Curr Opin Immunol 25: 1-3.
41. Haselberg R, Brinks V, Hawe A, de Jong GJ, Somsen GW, (2011) Capillary electrophoresis-mass spectrometry using noncovalently coated capillaries for the analysis of biopharmaceuticals. Anal Bioanal Chem 400: 295-303.
42. Sanchez-Hernandez L, Garcia-Ruiz C, Crego AL, Marina ML, (2010) Sensitive determination of D-carnitine as enantiomeric impurity of levo-carnitine in pharmaceutical formulations by capillary electrophoresis-tandem mass spectrometry. J Pharm Biomed Anal 53: 1217-1223.
43. Hommerson P, Khan AM, Bristow T, Harrison MW, de Jong GJ, et al. (2009) Drug impurity profiling by capillary electrophoresis/mass spectrometry using various ionization techniques. Rapid Commun Mass Spectrom 23: 2878-2884.
44. Simionato AV, Carrilho E, Tavares MF, (2011) Characterization of protein hydrolysates of cosmetic use by CE-MS. J Sep Sci 34: 947-956.
45. Sun Y, Sun G, Jin Y, (2008) [Quality control of traditional Chinese medicines by the capillary electrophoresis fingerprint and capillary electrophoresis-mass spectrometry]. Se Pu 26: 160-165.
46. Jähne J, Bonaparte C, Kühne M, Klein G, (2013) Viability of microencapsulated probiotic lactobacilli during storage at different temperatures. Berl München Tierärztl Wschr 126: 10-15.